
Scienta Lab is a deeptech company focused on revolutionizing precision immunology and drug development. Their explainable machine learning platform models immune-mediated inflammatory diseases to predict treatment efficacy and identify optimal therapies for individual patients. By integrating with global medical networks, Scienta Lab aims to answer complex questions regarding drug response variability in conditions like rheumatoid arthritis, lupus, and Crohn's disease. They partner with academic centers, researchers, and industry leaders to advance precision medicine in immunology. The company is building a multidisciplinary team of innovators passionate about this vision.

Scienta Lab is a deeptech company focused on revolutionizing precision immunology and drug development. Their explainable machine learning platform models immune-mediated inflammatory diseases to predict treatment efficacy and identify optimal therapies for individual patients. By integrating with global medical networks, Scienta Lab aims to answer complex questions regarding drug response variability in conditions like rheumatoid arthritis, lupus, and Crohn's disease. They partner with academic centers, researchers, and industry leaders to advance precision medicine in immunology. The company is building a multidisciplinary team of innovators passionate about this vision.
What they do: Explainable ML platform (EVA) for predicting human immune responses and guiding precision immunology
Headquarters: Gif-sur-Yvette / Paris‑Saclay area, France
Founded: 2021
Founders / leadership: Camille Bouget (CEO), Vincent Bouget (CSO), Julien Duquesne (CTO)
Funding signal: Multiple funding events including grants and Seed rounds; recent Seed on 2025-07-24
Precision immunology, immune‑mediated inflammatory diseases, translational research, clinical trial design
2021
Biotechnology
Latest announced Seed round
EIC Accelerator grant listed
“Includes European Innovation Council / EIC Accelerator, CentraleSupélec Venture, PharmStars and individual angels (e.g., Flavien Kulawik, Guillaume Amblard)”